Nov. 1 Webinar: Giving Care to the Caregiver: ... - CLL Support

CLL Support

22,532 members38,709 posts

Nov. 1 Webinar: Giving Care to the Caregiver: Dr. Allison Applebaum is the breath of fresh air we caregivers have been waiting for!

bkoffman profile image
bkoffmanCLL CURE Hero
0 Replies

CLL Society's Nov. 1 Webinar: Giving Care to the Caregiver with Allison Applebaum! Dr. Allison Applebaum is the breath of fresh air we caregivers have been waiting for! Studying caregivers with the penetrating eye of a scientist, Allison's work affirms the seriousness of our job, the range of emotions and depth of the fatigue we feel, the stress of setbacks, the exhilaration of seeing our patient improve, and much more. At one time, we caregivers were new to taking care of our patient, but acquired skills with practice. CLL Society recognizes that the skill of taking care of caregivers is an emerging field of study. Science is now looking at us, affirming our needs, and advising self care. Become inspired! Push the “refresh” button. Bring your caregiver, or show up if you are one! Next Monday. Don't miss it. Register now! cllsociety.org/giving-care-...

Written by
bkoffman profile image
bkoffman
CLL CURE Hero
To view profiles and participate in discussions please or .

You may also like...

Vaccines, 3rd dose, LLS results and more

in CLL and BTKi patients than in other studies. Most untreated or 1 year post treatment patients...

CLL SOCIETY'S ASH POSTER on our Free second opinion program plus two important papers from ASCO

abstract studies second cancers in CLL patients on ibrutinib or acalabrutib....

Worried About Going Back to Work?

about going back to work? The CLL Society continues to urge all CLL patients to strictly avoid...

Zanubrutinib vs. Ibrutinib Patient Power Video by Dr. Jennifer Brown MD PHD

updates our chronic lymphocytic leukemia (CLL) patients on the latest from the 2022 American...

Clinical Trials studying COVID-19 vaccines in CLL: Some have begun/ others are coming!

Trials studying COVID-19 vaccines in CLL: In response to all those who have reached out to CLL...